Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Publication number: 20200352964
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko ENDO, Kyohei TAKAHASHI, Shinya UMEZAKI
  • Publication number: 20200352852
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Application
    Filed: April 27, 2020
    Publication date: November 12, 2020
    Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
  • Publication number: 20200345713
    Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
    Type: Application
    Filed: December 27, 2018
    Publication date: November 5, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
  • Publication number: 20200316009
    Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.
    Type: Application
    Filed: December 20, 2018
    Publication date: October 8, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasuko YAMAMOTO, Takazumi TANIGUCHI
  • Patent number: 10786526
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 29, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Inagaki, Naoki Matsumoto, Toshihiro Ogawa, Yukihisa Wakabayashi, Asuka Kamimura, Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka
  • Publication number: 20200289483
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Patent number: 10765750
    Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 8, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Yoko Endo
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Publication number: 20200254000
    Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro OSHITA, Hitoshi NAKAZAWA, Isao MATSUOKA, Asuka KAMIMURA
  • Patent number: 10729712
    Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 4, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka, Asuka Kamimura
  • Publication number: 20200215093
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10702511
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 7, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20200206200
    Abstract: The object of the present invention is to find a new application of isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminometh yl}pyridin-2-ylamino) acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Najam A. SHARIF
  • Publication number: 20200188377
    Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.
    Type: Application
    Filed: September 27, 2018
    Publication date: June 18, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: TAKAZUMI TANIGUCHI, Takahiro AKAISHI, Hitoshi NAKAZAWA
  • Patent number: 10682340
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 16, 2020
    Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
  • Patent number: 10668011
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 2, 2020
    Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
  • Publication number: 20200165330
    Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 28, 2020
    Applicants: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
  • Publication number: 20200147222
    Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
    Type: Application
    Filed: March 13, 2017
    Publication date: May 14, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
  • Publication number: 20200147056
    Abstract: This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent.
    Type: Application
    Filed: May 25, 2017
    Publication date: May 14, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventor: Raj K. MATURI
  • Patent number: RE48183
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 1, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata